Show simple item record

dc.contributor.authorKhanal, Saval
dc.contributor.authorVeerman, Lennert
dc.contributor.authorNissen, Lisa
dc.contributor.authorHollingworth, Samantha
dc.date.accessioned2019-05-29T13:16:41Z
dc.date.available2019-05-29T13:16:41Z
dc.date.issued2019
dc.identifier.issn1759-8885
dc.identifier.doi10.1111/jphs.12265
dc.identifier.urihttp://hdl.handle.net/10072/382394
dc.description.abstractObjectives This research was aimed to forecast the amount and cost of medicines required to treat people with type 2 diabetes mellitus (T2DM) in Nepal over 30 years. Methods We modelled the financial burden of T2DM medicines by estimating the cost of medicines to treat all cases of T2DM in Nepal over three decades based on the prevalence of T2DM in Nepal, the Nepalese costs of medicine and the T2DM medicine use profile of Australia. Key findings With the current T2DM prevalence trend, it would cost US$63–95 million in 2013 to purchase T2DM medicines for Nepal, if Nepalese receive the same mix of T2DM medicines as used in Australia. This cost is almost one‐quarter of the total health budget of Nepal (US$308 million). The cost of medicines to treat T2DM is projected to triple between 2013 and 2043. Conclusions With the medicines for only T2DM projected to cost about 25% of the entire health budget, the planned health insurance seems unaffordable if patients are treated with the same medicines as those in one of the best healthcare systems in the world. The government needs to stimulate rational prescribing and secure additional funding through taxation, health insurance or health levy to provide such medicines and services.
dc.description.peerreviewedYes
dc.languageEnglish
dc.publisherWiley-Blackwell Publishing
dc.publisher.placeUnited Kingdom
dc.relation.ispartofpagefrom1
dc.relation.ispartofpageto9
dc.relation.ispartofjournalJournal of Pharmaceutical Health Services Research
dc.subject.fieldofresearchPharmacology and Pharmaceutical Sciences not elsewhere classified
dc.subject.fieldofresearchPharmacology and Pharmaceutical Sciences
dc.subject.fieldofresearchPublic Health and Health Services
dc.subject.fieldofresearchcode111599
dc.subject.fieldofresearchcode1115
dc.subject.fieldofresearchcode1117
dc.subject.keywordsPharmaco‐economics
dc.subject.keywordsNepal
dc.subject.keywordsModeling
dc.subject.keywordsHealth services research
dc.subject.keywordsAccess to medicine
dc.titleForecasting the amount and cost of medicine to treat type 2 diabetes mellitus in Nepal using knowledge on medicine usage from a developed country
dc.typeJournal article
dc.type.descriptionC1 - Articles
dc.type.codeC - Journal Articles
gro.facultyGriffith Health, School of Medicine
gro.hasfulltextNo Full Text
gro.griffith.authorKhanal, Saval
gro.griffith.authorVeerman, Lennert L.


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record